Leonard Zehr, Author at BioTuesdays

Feature

Korro Bio merger and financing to fuel RNA editing technology

Korro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s...

September 26, 2023

Feature

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...

September 19, 2023

Feature

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...

September 12, 2023

Feature

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.

September 5, 2023

Feature

Convergent readies IND for next-gen targeted radiotherapy

Closely-held Convergent Therapeutics is rapidly advancing a next generation alpha-emitting prostate-specific membrane antigen (PSMA)-targeted radioantibody for an IND filing in October.

August 29, 2023

Developments

XyloCor presents positive Phase 2 data for refractory angina

XyloCor Therapeutics presented positive results from the Phase 2 portion of its Phase 1/2 EXACT clinical trial of its lead gene therapy candidate, XC001, for the treatment of refractory angina at the European Society of...

August 25, 2023

Developments

EMA accepts Novaliq’s CyclASol for regulatory review in DED

The European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) from Novaliq GmbH for CyclASol (ciclosporin ophthalmic solution) for regulatory review. CyclASol is an investigational new...

August 24, 2023

Markets

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Cantor Fitzgerald downgraded Aravive (NASDAQ:ARAV) to “neutral” from “overweight” and slashed its price target to 25 cents from $18 after the company indicated it might be forced to cease operations. The stock closed at...

August 22, 2023

Feature

Halia targeting chronic inflammation to keep people healthier, living longer

Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and...

August 22, 2023

Feature

Immuneering developing medicines for cancer patients with RAS mutations

Immuneering (NASDAQ:IMRX) is integrating translational medicine with bioinformatics to discover and develop novel product candidates for a broad population of cancer patients with RAS mutations, an approach the company...

August 15, 2023

Author - Leonard Zehr

Korro Bio merger and financing to fuel RNA editing technology

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Convergent readies IND for next-gen targeted radiotherapy

XyloCor presents positive Phase 2 data for refractory angina

EMA accepts Novaliq’s CyclASol for regulatory review in DED

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Halia targeting chronic inflammation to keep people healthier, living longer

Immuneering developing medicines for cancer patients with RAS mutations

Subscribe